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Abstract
Background: Most extremely low gestational age neonates (ELGANS, postmenstrual age at birth (PMA) < 28
completed weeks) require supplemental oxygen and experience frequent intermittent hypoxemic and hyperoxemic
episodes. Hypoxemic episodes and exposure to inadequately high concentrations of oxygen are associated with an
increased risk of retinopathy of prematurity (ROP), chronic lung disease of prematurity (BPD), necrotizing
enterocolitis (NEC), neurodevelopmental impairment (NDI), and death beyond 36 weeks PMA.
Closed-loop automated control of the inspiratory fraction of oxygen (FiO2-C) reduces time outside the hemoglobin
oxygen saturation (SpO2) target range, number and duration of hypo- and hyperoxemic episodes and caregivers’
workload. Effects on clinically important outcomes in ELGANs such as ROP, BPD, NEC, NDI and mortality have not
yet been studied.
Methods: An outcome-assessor-blinded, randomized controlled, parallel-group trial was designed and powered to
study the effect of FiO2-C (in addition to routine manual control (RMC) of FiO2), compared to RMC only, on death
and severe complications related to hypoxemia and/or hyperoxemia. 2340 ELGANS with a GA of 23 + 0/7 to 27 + 6/
7 weeks will be recruited in approximately 75 European tertiary care neonatal centers. Study participants are
randomly assigned to RMC (control-group) or FiO2-C in addition to RMC (intervention-group). Central
randomization is stratified for center, gender and PMA at birth (< 26 weeks and ≥ 26 weeks).
FiO2-C is provided by commercially available and CE-marked ventilators with an FiO2-C algorithm intended for use
in newborn infants. The primary outcome variable (composite of death, severe ROP, BPD or NEC) is assessed at 36
weeks PMA (or, in case of ROP, until complete vascularization of the retina, respectively). The co-primary outcome
variable (composite outcome of death, language/cognitive delay, motor impairment, severe visual impairment or
hearing impairment) is assessed at 24 months corrected age.
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Discussion: Short-term studies on FiO2-C showed improved time ELGANs spent within their assigned SpO2 target
range, but effects of FiO2-C on clinical outcomes are yet unknown and will be addressed in the FiO2-C trial. This will
ensure an appropriate assessment of safety and efficacy before FiO2-C may be implemented as standard therapy.
Trial registration: The study is registered at www.ClinicalTrials.gov: NCT03168516, May 30, 2017.
Keywords: Oxygen, Closed-loop automated control of the inspiratory fraction of oxygen (FiO2-C), Infant, premature,
Intermittent hypoxemia and hyperoxemia
Background
Approximately 0.5% of all neonates (i.e., about 25,000
infants per year in Europe) are extremely low gesta-
tional age neonates (ELGANs), i.e. have a gestational
age at birth (GA) < 28 completed weeks. The vast majority
of ELGANs requires supplemental oxygen in addition to
positive pressure respiratory support and frequently ex-
perience intermittent hypoxemic and hyperoxemic epi-
sodes. Intermittent hypoxemic episodes are predominantly
caused by recurrent apnea due to immature development
of the respiratory neuronal network (recently reviewed [1,
2]) but also secondary to active exhalation during mechan-
ical ventilation [3]. Hyperoxemic episodes are usually a
consequence of inappropriate adjustments of FiO2 (during
routine manual control of FiO2 (RMC) but potentially also
during closed-loop automated control of FiO2 (FiO2-C)).
Complications of prematurity associated with recurrent
hypoxemic episodes
Retinopathy of prematurity (ROP)
Observational data indicated that both, severe and pro-
longed hypoxemic episodes [4–6], and wide fluctuations
in oxygen levels [7], increase the risk of ROP. Whereas a
better control of SpO2-levels was associated with a de-
creased risk of ROP [8].
Death and neurodevelopmental impairment (NDI)
Observational studies (recently reviewed in [9]) as well
as SpO2 data recorded during the Canadian Oxygen
Trial (COT [10],) suggest that late deaths (i.e. deaths be-
yond 36 weeks postmenstrual age (PMA)) and NDI (both
cognitive and particularly motor impairment) are linked
to hypoxemic episodes, particularly those of more than
60s duration [6].
Necrotizing enterocolitis (NEC)
The NeOProM (Neonatal Oxygen Prospective Meta-
analysis) collaboration reported a lower rate of severe
NEC (defined as NEC leading to abdominal surgery or
death) in infants assigned to the higher SpO2 target
range (91–95% compared to 85–89%) [11], which was
linked to a lower proportion of time spent with
SpO2 < 80%.
Complications of prematurity associated with
hyperoxemic episodes
Considering that breathing room air (i.e., FiO2 = 0.21)
leads to a relative hyperoxia compared to intrauterine
oxygen partial pressures (PO2) and oxidative stress in
preterm infants, hyperoxia, caused by inadequately high
FiO2, is likely associated with long-term adverse effects
[12].
ROP
The causal relationship between prolonged inappropriate
exposure to high oxygen concentrations and ROP has
long been established [13, 14]. More recently, the NeO-
ProM studies showed increased rates of ROP with the
higher SpO2-target range (91–95%) [11]. Finally, imple-
mentation of the higher SpO2-target range based on the
results of the NeOProM studies, was associated with an
increase in ROP rates in a recent observational study
[15].
Death and NDI
Data from experimental studies in rodents indicate that
higher levels of oxygen (e.g., FiO2 0.80 for 2 to 24 h [16–
18]) trigger apoptotic neurodegeneration or white matter
damage in the brain. These effects have been reviewed
by Back et al. [19].
Chronic lung disease of prematurity (BPD)
Hyperoxia enhancing generation of reactive oxygen spe-
cies triggers inflammatory processes, tissue damage and
cell death in the preterm infant’s lung, eventually result-
ing in an increased risk of BPD development (recently
reviewed in [20]).
Controlling of FiO2
To protect ELGANs from the detrimental effects of hyp-
oxemic and hyperoxemic episodes, it can be assumed
that PO2 (and in appropriate simplification SpO2) must
be kept within a narrow target range. To achieve this
goal despite the infants’ irregular breathing patterns and
variations in lung aeration and function, frequent cau-
tious adjustments of FiO2 are required, which are chal-
lenging, time consuming and often impossible due to
limited personnel resources.
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It has repeatedly been shown that FiO2-C increases
the time infants spent within the SpO2-target range and
reduces the burden of hyper−/hypoxemia while being
safe and accurate in short-term studies (reviewed in [21,
22]). The effects of FiO2-C on clinically relevant out-
comes measures (such as the hypoxia and hyperoxia-
associated complications of prematurity described
above) and the safety of its long-term continuous appli-
cation, however, have yet to be elucidated.
Methods/design
Trial objectives
The proposed trial was designed and is powered to com-
pare the effect of FiO2-C in addition to manual adjust-
ments, in comparison with RMC of FiO2 only, on death,
NDI and severe complications of prematurity thought to
be related to hypoxia/hyperoxia in ELGANs.
Trial design
This is an outcome-assessor-blinded, randomized-
controlled, multicenter parallel group comparison of
phase III for superiority (evaluating FiO2-C in addition
to RMC of FiO2 in comparison to RMC of FiO2 only) in
ELGANs.
In Germany, this study is also considered as a phase
IV pharmaceutical trial on safety of the investigational
medication ‘oxygen’ using different modes of administra-
tion (decision of the German authority BfArM according
to §4 para. 23,1 of the German Pharmaceutical Act).
This may not apply to other countries.
Setting
Patients will be recruited in approximately 75 European
tertiary care neonatal centers. Recruitment has started in
Germany and is intended to expand to additional sites in
other European countries, after appropriate approvals
will have been obtained.
Patients
Inclusion criteria
 GA at birth 23 + 0/7 to 27 + 6/7 weeks
Exclusion criteria
 Decision not to provide full life support / decision
for palliative care only before study entry
 Severe congenital abnormalities (particularly those
affecting respiratory, cardiovascular or
gastrointestinal function or long-term neuro-
cognitive development, whereas patent ductus arter-
iosus, patent foramen ovale (PFO), and atrial septal
defects type II (ASDII) are not considered a congeni-
tal anomaly in preterm infants)
 Postnatal age > 48 h
 Lack of parental consent
 Lack of device enabling closed-loop automatic con-
trol of FiO2 before randomization
Randomization and allocation concealment
Study participants are randomly assigned in a 1:1 ratio
to FiO2-C in addition to RMC of FiO2 (test intervention)
or RMC of FiO2 only (control intervention).
A web-based randomization tool provided by the
Interdisciplinary Center of Clinical Studies at the Uni-
versity Medical Center of the Johannes Gutenberg Uni-
versity Mainz is being used in this study. This program
enables bound (into the same treatment group) or free
(into different treatment groups) randomization of mul-
tiples based on parental choice and the number of avail-
able devices enabling FiO2-C.
A minimization algorithm is applied to preferentially
aim for an even distribution of treatment assignment in
both GA strata (i.e. < 26 weeks and ≥ 26 weeks; 1st prior-
ity) and both gender strata (2nd priority) within each
center.
Blinding
This study is outcome-assessor-blinded, meaning that
the personnel performing the ophthalmological exami-
nations throughout the initial hospitalization as well as
the personnel performing the neurocognitive evaluation
at 24 months corrected age will be blinded to the infants’
treatment group assignment. Blinding of doctors, nurses,
and parents is not possible with this type of study
interventions.
Study intervention
FiO2-C is provided by commercially available and CE
marked infant ventilators with a FiO2-C algorithm
intended for use in preterm infants. The FiO2-C algo-
rithm must have been tested in human infants and
shown to increase the %-time spent in the assigned
SpO2 target range or to reduce the time in hypoxemia
or hyperoxemia or to reduce the incidence/duration of
hypoxemic or hyperoxemic episodes.
Each FiO2-C algorithm should be applied in its “opti-
mal mode” (with respect to potentially variable settings
provided by the manufacturer such as: averaging time of
SpO2-input, response/wait-time, etc.) based on either
evidence in the literature or consensus of the users.
Manual adjustments are encouraged whenever auto-
matic FiO2 settings seem sub-optimal. In case of FiO2/
SpO2-oscillations brought about by FiO2-C, settings
need to be adapted or FiO2-C has to be temporarily
interrupted.
Whenever possible, every study center will use only
one type of FiO2-C algorithm.
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Infants in the control group are treated (whenever
possible) with the same type of infant ventilator for re-
spiratory support (FiO2-C turned off) and RMC of FiO2
is applied by bedside nurse and medical staff throughout
the initial hospitalization.
Care is taken in both groups that all staff are informed
about the relevance of intermittent hypoxemia and hyper-
oxemia and trained to execute prudent and careful RMC
of FiO2. This training may include a standard operating
procedure for RMC, where the speed of increase/decrease
in FiO2 depends on the magnitude of deviation from the
SpO2 target range as previously described [23, 24].
The intervention should start as soon as possible after
randomization and within 48 h after birth. The sched-
uled end of the study intervention is any of the following
(whichever comes first):
 death
 discharge home from hospital
 transfer to another hospital where FiO2-C is not
available (whereas such transfer is discouraged)
 a PMA of 36 + 0/7 weeks
 final discontinuation of positive pressure respiratory
support, which does not include limited periods
without positive pressure support for weaning.
If the infant requires positive pressure respiratory
support again for any reason, the infant should again
be supported by FiO2-C (provided a device
supporting FiO2-C is available) until (other) criteria
for scheduled end of study intervention are met.
 a PMA of > 32 + 0/7 weeks provided the following
two additional criteria of respiratory stability are
both met:
 A) FiO2 = 0.21 for ≥48 h (for this criterion limited
time periods with higher FiO2 for rescue or for
recovery of intermittent hypoxemia will not be
considered)
and
B) less than 5 intermittent hypoxemic episodes with
an SpO2 < 80% per 8 h shift.
If criteria A) or B) are no longer met, the infant should
again be supported by the FiO2-C device until (other) cri-
teria for scheduled end of study intervention are met.
 a PMA of > 32 + 0/7 weeks if the infant has to be
transferred to an intermediate care unit where FiO2-
C is not available
If the infant is re-admitted to intensive care, the infant
should again be supported by FiO2-C (provided a device
supporting FiO2-C is available) until (other) criteria for
scheduled end of study intervention are met.
After the end of the study intervention, all study par-
ticipants will be treated according to the state of the art
care and local standards without further requirements or
restrictions.
Concomitant interventions and medication
Any concomitant medication that is clinically considered
necessary for the patient will be allowed within the
study, except for the control group, where closed-loop
automatic control of FiO2 or any other automatic con-
trol of airway pressure/respiratory support etc. based on
SpO2 or other vital signals are not allowed.
SpO2 measurements to guide FiO2-C
All FiO2-Controllers should be based on SpO2-data gen-
erated by the same pulse oximeter technology (Masimo).
In general, pre-ductal SpO2-sensor placement is pre-
ferred to guide FiO2-C as long as echocardiography
demonstrates a patent ductus arteriosus.
SpO2-targets and alarm settings
The SpO2-target range selected by a center for clinical
routine has to fulfill the following criteria:
 Study centers need to have a written guideline on
SpO2-target range to ensure that the same SpO2-
target range is applied in both study groups
 The SpO2-target has to be within the range of 87–
95% (may include 87% and/or 95%),
 Care has to be taken that the same SpO2-target
ranges are applied in clinical routine and in both
study groups
Documentation of the study intervention
In both study groups, the type of respiratory support,
the type of ventilator and the application of FiO2-C have
to be documented daily during the intervention period
on a treatment log.
Primary outcome
The primary outcome measure is a composite of death,
BPD or NEC assessed at 36 weeks PMA and severe ROP
assessed when full vascularization of the retina is
documented.
Definitions of components of the primary outcome
Severe ROP
Defined as any ROP stage 3 or higher, or acute posterior
ROP, or any ROP in Zone 1, or any treatment for ROP.
ROP will be diagnosed at routine ophthalmological ex-
aminations, beginning at a PMA of 32 weeks according
to international recommendations and local standards
until complete vascularization of the retina [25]. The se-
verity of ROP will be graded according to the inter-
national classification [26].
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BPD
Defined as requiring positive pressure support or supple-
mental oxygen at 36 weeks ±2 days PMA, including an
oxygen reduction test for infants requiring less than 0.3
FiO2, representing ‘moderate’ or ‘severe’ BPD according
to the National Institute of Child Health and Develop-
ment consensus definition [27].
NEC
Defined as modified Bell stage ≥IIa [28] until 36 weeks
PMA.
Co-primary outcome
The co-primary outcome (tested in a hierarchical design) is
the composite outcome of death, language or cognitive
delay, motor impairment, severe visual impairment or hear-
ing impairment, all assessed at 24 ± 1months corrected age.
Definitions of components of the co-primary outcome
Language or Cognitive delay: Defined as a language or
cognitive composite score at the Bayley Scales of Infant
Development 3rd edition [29] of < 85.
Motor impairment: Defined as a Gross Motor Func-
tion Classification System (GMFCS) score of 2–5 [25].
Severe visual impairment: Defined as best corrected vi-
sion in the better eye yields a visual acuity less than 6/
60 m (20/200 ft) according to the relevant doctor’s re-
ports / discharge summary.
Severe hearing impairment: need for a hearing aid or
cochlear implant.
Any clinical suspicion of previously undiagnosed visual
or hearing problems during the FiO2-C follow-up visit
requires a referral to an eye specialist or an
pedaudiologist.
If the parents refuse the assessment at the study center
or if Bayley test cannot be performed:
Other assessments of neurocognitive and motor devel-
opment will betaken into account, if parents refuse to at-
tend the follow-up.
Cognitive- and language-composite-scores will then be
imputed as follows:
A score “> 85” will be imputed if
 a different cognitive test has been performed elsewhere
and scored higher than 1SD below the mean
 the family pediatrician/doctor/health professional
caring for the child or the parents rate the infant as
“normal”
A score “< 85” will be imputed if
 a different cognitive test has been performed
elsewhere and scored lower than 1SD below the
mean
 the family pediatrician/doctor/health professional
caring for the child or the parents rate the infant as
“delayed” or “impaired”.
Any such imputation will be described in the final
report and the scientific publication.
Secondary outcomes
Key secondary outcome variables are the individual
components of the primary (death, severe ROP, BPD,
NEC) and co-primary outcome variables (death, cogni-
tive delay or language delay, motor impairment (GMFCS
score of 2–5 [30]), as well as severe visual or hearing im-
pairment,, the composite scores of the Bayley Scales (3rd
edition), the rate of cerebral palsy (CP) according to the
criteria defined by the European network ‘Surveillance of
CP in Europe’, and the GMFCS score.
In addition to ‘severe ROP’ as component of the pri-
mary outcome, the ‘ROP Severity Score’ (also entitled
‘ROP activity and structure score’) [31] is assessed as
secondary outcome, enabling better differentiation and
likely being more relevant for functional outcome.
Ethical considerations
The Helsinki Declaration shall be applied to the clinical
trial, as well as Good Clinical Practice (GCP). The proto-
col was submitted and approved by the Ethics Commit-
tee of the University Hospital Tübingen as the lead
ethics committee. Furthermore, the relevant ethics com-
mittees responsible for any of the participating study
sites will have to approve participation of the site.
Community engagement
A freely accessible web page for FiO2-C has been set up
(www.fioc-study.eu), providing an overview of aims,
partners, study outline, progress and milestones, meet-
ings, findings and news.
Form of consent
Written informed consent from parents or legal guard-
ians is required for participation in the study.
Insurance
Where required by national law, insurance will be ob-
tained for all study patients.
Sample size, power and study duration
The required sample size was calculated for the primary
research hypothesis that the implementation of FiO2-C
reduces the cumulative incidence of the composite pri-
mary outcome (death, severe ROP, BPD, or NEC).
The co-primary research hypothesis is that FiO2-C
also reduces death or severe NDI (see outcome measures
for details). These hypotheses are assessed as a-priori
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ordered hypotheses, where the co-primary hypothesis
will only be tested in a confirmatory manner if the pri-
mary hypothesis has been confirmed. Consequently, no
correction for multiple testing will be performed.
We assume that,
a) the cumulative incidence of the primary composite
outcome of this study is 50% in the control group
b) FiO2-C reduces the burden of severe hypoxemia/
hyperoxemia by 25–50% and (based on the
assumption that (again) 25–50% of the outcome is
associated with recurrent hypo−/hyperoxemia)
effects a relative risk reduction in this outcome by
at least 12.5%.
In summary, we assume a reduction in the primary
outcome from 50% (in the control group) to 44% in the
intervention group (FiO2-C).
Sample size calculations were based on a Χ2-test, as-
suming a power of 80% and a significance level of 5%.
Based on these assumptions, 1110 infants are required in
each treatment group (total 2220 infants). Because all
components of this primary outcome will be determined
during the initial hospitalization (i.e. until first discharge
from neonatal care), the rate of drop-out before ascer-
tainment of the primary outcome will be low as < 5%.
Hence, a total of 2340 infants need to be enrolled and
randomized (see Fig. 1).
Assuming an incidence of 50% for the co-primary out-
come in the control group and a relative risk reduction
(RRR) of 25% for the co-primary outcome in the FiO2-C
group, the proposed sample size will have a power > 80%
to prove this difference even if up to 20% of randomized
infants will be lost to follow-up until 24 months cor-
rected age.
It is estimated that about 90% of all ELGANs will
qualify for inclusion into this study without any exclu-
sion criteria. Estimating a participation rate of 80%, ap-
proximately 3350 infants have to be screened.
We estimate a recruitment of about 65 patients per
month and therefore the recruitment phase of the study
will last for approximately 36 months. The individual
participation in the study will be about 27 months (be-
tween 56 and 91 days of treatment – depending on GA
at birth - with an additional follow up to 24 months cor-
rected age).
Data analysis
Analysis of the primary outcome will be based on the
intention to treat analysis set, which comprises all ran-
domized patients. Portions of infants with primary end-
point will be compared in a statistical model that accounts
for the factors considered by the randomization procedure
and the randomization of twins and other multiples. The
treatment effect will be reported as a risk ratio and as a
risk difference with 95% confidence interval. The co-
primary outcome will be assessed only if superiority of
FiO2-C with respect to the primary outcome is confirmed
at the 2-sided level of 0.05. This hierarchical testing pro-
cedure maintains a multiple type I error of 0.05. All statis-
tical analyses will be described in detail in a statistical
Fig. 1 Anticipated Trial Flow
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analysis plan completed before closure of the database. An
interim analysis for efficacy is not intended.
Monitoring safety
An independent Data Monitoring Committee (DMC) is
instituted and monitors recruitment, compliance, and
safety parameters after 50, 100, 200 and 300 patients
have completed 44 + 0/7 weeks PMA, and after every
200 patients have reached this age thereafter.
Safety parameters
Safety parameters monitored by the DMC include:
Early deaths (for the DMC defined as < 44 weeks
PMA), late deaths (for the DMC defined as ≥44 weeks
PMA), all deaths, BPD, discharge on home oxygen or
home positive pressure respiratory support, severe ROP,
NEC, (focal) intestinal perforation requiring laparotomy,
PDA requiring treatment, intraventricular hemorrhage
>grade 2, cystic periventricular leukomalacia. Because
the safety parameters include components of the primary
outcome, the incidence rates and 95% confidence intervals,
these parameters will be ‘coded’ as “safety parameter A-I”.
Furthermore, safety analyses include occurrence and
rates of reported adverse events and incidents by treat-
ment group.
Regulatory aspects
Trial sponsor
Sponsor of the FiO2-C-trial is the University Hospital
Tübingen, Geissweg 3, 72,076 Tübingen, Germany. Con-
tact is available at fioc@med.uni-tuebingen.de.
Medical ethics committees
At the time of submission, the relevant ethics committee
in Germany approved the study. Applications for ap-
provals are currently underway in additional countries
(e.g., the Netherlands and Switzerland).
National Regulatory/competent authorities
At the time of submission, the National Regulatory/
Competent Authority of Germany (BfArM) approved
the study. Authority approval may not be necessary else-
where – but this will be determined in collaboration
with the relevant ethics committees.
Discussion
Need for a trial
Oxygen is one of the drugs most frequently used in
ELGANs and yet, our knowledge on the optimal level of
oxygen in arterial blood (or in appropriate simplification
the optimal target range for SpO2) and even optimal
technology for monitoring oxygen levels is incomplete
[32–34]. Short-term studies in preterm infants demon-
strated that FiO2-C improved the time within the
assigned SpO2 target range. In these studies, percent
time within the assigned SpO2 target range increased by
approximately 10% points to around 70–90% and the
improvement was independent of the SpO2 target range,
the FiO2-C algorithm, and the proportion of time spent
within SpO2 target range in the control-group [21, 22,
35, 36]. It is, however, unclear if more time spent within
the assigned SpO2 target range will also translate into
positive long-lasting effects on clinically relevant out-
comes. For example, despite higher proportions of time
spent within the SpO2 target range, FiO2-C might on the
one hand side reduce the amplitude of SpO2 fluctua-
tions, but, at the same time increase the frequency of
SpO2 oscillations and thereby might carry additional
risks. This randomized controlled trial will ensure an ap-
propriate assessment of safety and efficacy of FiO2-C,
before it is implemented into standard care.
Discussion of the study intervention period
The study intervention period was chosen because Di
Fiore et al. showed that hypoxemic episodes evolve over
the first 2 weeks of life and hence starting the interven-
tion within 48 h after birth seems appropriate. This will
enable a reasonable time frame to inform parents, even if
birth of the infant occurs at night or on weekends, and to
enable a meaningful parental decision on participation.
As described by Di Fiore et al. [5] and confirmed by
Poets et al. [6], hypoxemic episodes occurring beyond
the 4th week of life are more strongly associated with
adverse long-term outcomes than hypoxemic episodes
occurring within the first 4 weeks of life. Hence, the
study intervention should not end at 32 weeks PMA. In-
fants with prolonged and frequent hypoxemic episodes
beyond this age may benefit most from effective FiO2-C.
Discussion of chosen population
Because diseases thought to be related to inappropriate
use of oxygen such as ROP and BPD essentially only
occur in ELGANs, an assessment of efficacy and safety
of long-term application of FiO2-C can only be per-
formed in this patient population.
Discussion of chosen SpO2-target range
The NeOProM collaboration has shown that the higher
SpO2-target range of 91 to 95% is associated with a de-
creased risk of early deaths at 18 to 24months corrected
age and NEC, but with an increased risk of ROP [11].
Furthermore, a post-hoc analysis of the BOOST-II data
indicated that a higher proportion of time within the
assigned target range could enhance this beneficial effect
[37]. Consequently, in the FiO2-C trial the lower limit of
the center-specific SpO2 target range has to be set to
≥87% SpO2.
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Trial status
Protocol version 4: April, 26th, 2018. Recruitment has
started in July 2018 and is expected to be finalized in
July 2021. The last patient out (after follow-up) will be
expected in October 2023.
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